Hdac inhibitor trichostatin a suppresses esophageal squamous cell carcinoma metastasis through hadc2 reduced mmp-2/9

Clinical and Investigative Medicine

Volumn 36, Issue 2, 2013, Pages

  Wang, Feng ^a   Qi, Yu ^a   Li, Xin ^a   He, Wei ^a   Fan, Qing Xia ^a   Zong, Hong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRICHOSTATIN A;

ARTICLE; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA, SMALL INTERFERING;

EID: 84877053541     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics. CA Cancer J Clin. 2005; 55:74-108.
2. Zhou, X.B., Guo, M., Ŷuan, L.P., Zhang, W., Lu, Z.M., Wang, Q.H., et al., Detection of human papillomavirus in Chinese esophageal squamous cell carcinoma and its adjacent normal epithelium. World J Gastroenterol, 2003; 9:1170-3.
3. Li, X.D., Huang, X.P., Zhao, C.X., Li, Q.J., Xu, X., Cai, Y., et al., Identification of a minimal deletion region on chromosome 5q in Chinese esophageal squamous cell carcinomas. Cancer Lett, 2004; 215:221-228.
4. Wang, B.Y., Goan, Y.G., Hsu, P.K., Hsu, W.H., Wu, Y.C., Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 91:887-93.
5. Kimura, S., Naganuma, S., Susuki, D., Hirono, Y., Yamaguchi, A., Gujieda, S., et al., Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep. 2010; 23:1625-33.
6. Stratton, M.R., Campbell, P.J., Futreal, P.A., The cancer genome. Nature, 2009; 458:719-24.
7. Marks, P.A., The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 19:1049-66.
8. Spiegel, S., Milstein, S., Grant, S., Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 31:537-51.
9. Fritsche, P., Seidler, B., Schüler, S., Schnieke, A., Göttlicher, M., Schmid, R.M., et al., HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut, 2009; 58:1399-409.
10. Jurkin, J., Gordin, Z., Sabine, L., Reinhard, G., Astrid, H., Lukas K., et al., Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle. 10:406-12.
11. Krämer, O.H., HDAC2: a critical factor in health and disease. Trends Pharmacol Sci, 2009; 30:647-55.
12. Harms, K.L. and Chen, X.B., Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res, 2007; 67: 3145-52.
13. Bicaku, E., Marchion, D.C., Schmitt, M.L., Münster, P.N., Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res, 2008; 68:1513-9.
14. Ropero, S., Fraga, M.F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., et al., A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet, 2006; 38:566-9.
15. Vigushin, D.M., Ali, S., Pace, P.E., Mirsaidi, N., Ito, K., Adcock, I., et al., Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res, 2001; 7:971-6.
16. Huang, L., Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol, 2006; 209:611-6.
17. Ahmad, M., Hamid, A., Hussain, A., Majeed, R., Ŷurishi, Y., Bhat, J.A., et al., Understanding Histone Deacetylases in the Cancer Development and Treatment: An Epigenetic Perspective of Cancer Chemotherapy. DNA Cell Biol.
18. Vanhaecke, T., Papeleu,P., Elaut, G., Rogiers, V., Trichostatin Alike hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem, 2004; 11:1629-43.
19. Aghdassi, A., Sendler, M., Guenther, A., Mayerle,, J., Behn, C.O., Heidecke, C.D., et al., Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut. 61:439-48.
20. Yang, X.J. and Seto, E., The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol, 2008; 9:206-18.
21. Clayton, A.L., Hazzalin, C.A., Mahadevan, L.C., Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell, 2006; 23:289-96.
22. Kim, M.S., Kwon, H.J., Lee, Y.M., Baek, J.H., Jang, J.E., Lee, S.W., et al., Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med, 2001; 7:437-43.
23. Wu, Y., Starzinski-Powitz, A., Guo, S.W., Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci, 2007; 14:374-82.
24. Matsushima, K., Isomoto, H., Kohno, S., Nakao, K., MicroRNAs and esophageal squamous cell carcinoma. Digestion. 82:138-44.
25. Zeh, H.J., 3rd and M.T. Lotze, Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother, 2005; 28:1-9.
26. Chang, C.C., Lin, B.R., Chen, S.T., Hsieh, T.H., Li, Y.J., Kuo, M.Y., HDAC2 promotes cell migration/invasion abilities through HIF-1alpha stabilization in human oral squamous cell carcinoma. J Oral Pathol Med. 2011;40:567-75.
27. Wu, L.M., Yang, Z., Zhou, L., Zhang, F., Xie, H.Y., Feng, X.W., et al., Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBVassociated hepatocellular carcinoma. PLoS One. 5:e14460.
28. Kim, Y., Park, H., Park, D., Lee, D., choe, J., Hahn, J.H., et al., Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anticancer drugs. J Biol Chem. 2010; 285:25957-68.
29. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., et al., A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 1994; 370:61-5.
30. Vihinen, P., Kähäri, V.M., Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer, 2002; 99:157-66.
31. Li, Y., Ma, J., Guo, Q., Duan, F.L., Tang, F.A., Zheng, P.Y., et al., Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. Dis Esophagus, 2009; 22:664-7.
32. Liu L.T., Chang H.C., Chiang L.C., Hung W.C., Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 2003;63:3069-72.
33. Vincenti, M.P., Brinckerhoff, C.E., Signal transduction and celltype specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol, 2007; 213:355-64.
34. Jeon, H.W., Lee, K.J., Lee, S.H., Kim, W.H., Lee, Y.M., Attenuated expression and function of the RECK tumor suppressor under hypoxic conditions is mediated by the MAPK signaling pathways. Arch Pharm Res. 34:137-45.
35. Furumai, R., Komatsu., Y., Nishino, N., Khochbin, S., Yoshida, M., Horinouchi, S., Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A, 2001; 98:87-92.
36. Yasui, W., Oue, N., Ono, S., Mitani, Y., Ito, R., Nakayama, H., Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci, 2003; 983:220-31.
37. Meng, J., Zhang, H.H., Zhou, C.X., Li, C., Zhang, F., Mei, Q.B., The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53- dependent and -independent pathways. Oncol Rep. 28:384-8.
38. Drzewiecka, H., Jagodzinski, P.P., Trichostatin A reduced phospholipase C gamma-1 transcript and protein contents in MCF-7 breast cancer cells. Biomed Pharmacother. 2012; 66:1-5.